{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:57:07Z","timestamp":1791190627779,"version":"4.1.0"},"reference-count":28,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologica"],"abstract":"<jats:p>Introduction: The SHIFT-HB study (SwitcH Faricimab Treatment in High Burden patients) aimed to evaluate the anatomical and functional outcomes \u2013 and the short-term stability of extended dosing intervals \u2013 after switching to faricimab in high treatment burden (HB) neovascular age-related macular degeneration (nAMD) previously treated with first-generation anti-VEGF agents. The primary aim was to assess treatment interval changes after 6 intravitreal injections (IVIs) and the stability of interval gains between the 5th and 6th faricimab IVI. Methods: Single-center, retrospective real-world study (November 2023-November 2024; tertiary center Edouard Herriot Hospital, Lyon). Eligible eyes had nAMD requiring \u22648-week intervals despite \u22656 prior aflibercept or ranibizumab injections. After the switch, all eyes received \u22656 faricimab IVIs under a proactive Treat-and-Extend regimen. Short-term stability was defined, among eyes with any interval gain, as a prescribed interval at V6 identical to or longer than that at realized at V5. Results: In total, 190 eyes from 158 patients (mean age 81 \u00b1 7.5 years; 57.9% female) were included. The mean pre-switch interval was 4.9 \u00b1 1.2 weeks and increased to 6.7 weeks after 6 faricimab IVIs (p = 5.85 \u00d7 10\u221220). Interval increased in 61.6% of eyes; among these, 45% gained \u22653 weeks (range +3 to +8). Short-term stability between V5 and V6 occurred in 82.3% of responders. The maximum interval was first achieved at V6 in 52.1% of responder eyes. Among eyes with paired baseline and V6 measurements, best-corrected visual acuity remained stable (69.2 vs. 71.2 ETDRS letters; p = 0.67), while central retinal thickness decreased (303.1 \u00b5m\u2013287.2 \u00b5m; p = 9.98 \u00d7 10\u22124). Intraocular inflammation occurred in 7 eyes (3.7%; 0.61% of injections) and led to drug discontinuation. Conclusion: In real-world HB nAMD, switching to faricimab enabled a significant extension of injection intervals in nearly two-thirds of eyes while maintaining vision and improving OCT anatomy, supporting faricimab as a strategy to reduce treatment burden in this difficult-to-treat population.<\/jats:p>","DOI":"10.1159\/oph\/aeeag007","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:03:05Z","timestamp":1786021385000},"page":"1-1","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Treatment Interval Extension and Short-Term Interval Stability after Switching to Faricimab in Neovascular AMD: A Mid-Term Observational Study"],"prefix":"10.1159","author":[{"given":"Benjamin","family":"Simond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Fenniri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chirpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Elbany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Gilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Chacun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Voirin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Burillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Matagrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3978","authenticated-orcid":false,"given":"Corinne","family":"Dot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.05.035"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04456-2"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070459"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2639"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S395279"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2024.07.020"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00288-0"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02231-y"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03364-y"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06319-3"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-025-07091-2"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004322"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409822"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155145"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-023-01024-4"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00779-w"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06222-x"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.08.018"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/life14020193"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2025.100744"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S424315"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03015-2"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054676"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19772"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.08.008"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2026.104821"}],"container-title":["Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/oph\/aeeag007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:47:57Z","timestamp":1791190077000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/oph\/aeeag007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1159\/oph\/aeeag007","archive":["Portico"],"relation":{},"ISSN":["0030-3755","1423-0267"],"issn-type":[{"value":"0030-3755","type":"print"},{"value":"1423-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}